Lehr

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

Retrieved on: 
Tuesday, October 31, 2023
IND, CD3, Lehr, Context, CLDN6, SITC, Immunotherapy, Annual general meeting, Benchmarking, Path integral molecular dynamics, Society, Patient, Drug discovery, Toxicity, Abstract, Fine chemical, Pharmaceutical industry

PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.

Key Points: 
  • PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
  • Findings from Context’s research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.
  • Notably:
    CTIM-76 was shown to have high potency and target selectivity in both binding and cytotoxicity assays.
  • “The preclinical data at this year's SITC meeting will illustrate the potential of CTIM-76 to target CLDN6,” said Lehr.

"A Beautiful Noise: The Neil Diamond Musical" Cast Presents Parkinson's Foundation with a $500,000 Donation

Retrieved on: 
Wednesday, April 12, 2023
Breast Cancer Awareness Month, Songwriters Hall of Fame, Music, Grammy Award for Songwriter of the Year, Non-Classical, PD, Beautiful Noise, Parkinson's Foundation, Believer, A Beautiful Noise, Rock & Roll Hall of Fame Covers EP, Cracklin' Rosie, Retirement, Parkinson's disease, Rock, Baseball Hall of Fame balloting, Grammy Awards, Broadway, Diagnosis, Sweet Caroline, Imagination, Noise, Lehr, Nightclub, Diamond

On Tuesday, April 11, following the show's final bow, the cast revealed the final total from their fundraising efforts.

Key Points: 
  • On Tuesday, April 11, following the show's final bow, the cast revealed the final total from their fundraising efforts.
  • A check for $500,000 was presented by A Beautiful Noise co-producers Jonathan Corr and Sandi Moran to Parkinson's Foundation President and CEO John L. Lehr.
  • "Shortly after her passing, I was presented with the once-in-a-lifetime opportunity to join the producing team of A Beautiful Noise.
  • To support A Beautiful Noise: The Neil Diamond Musical's fundraising efforts, visit Parkinson.org/BeautifulNoise .

Mayville Engineering Company, Inc. Announces Appointment of Rachele Lehr as Chief Human Resources Officer

Retrieved on: 
Monday, March 13, 2023
Manufacturing, Other Manufacturing, Steel, Engineering, Machine Tools, Metalworking & Metallurgy, Business administration, Marquette University, Lehr, NYSE, Briggs & Stratton, HR, LLP, Organization, Senior, Mayville, Oklahoma Secretary of Human Resources and Administration, Human resources, Controller, Acquisition, MEC, Administration, Growth, PwC, Information, Management, Science

Mayville Engineering Company (NYSE: MEC, the “Company” or “MEC”), a leading U.S.-based value-added manufacturing partner that provides a full suite of services from concept to production, today announced the appointment of Rachele Lehr as the Chief Human Resources Officer, effective March 13, 2023.

Key Points: 
  • Mayville Engineering Company (NYSE: MEC, the “Company” or “MEC”), a leading U.S.-based value-added manufacturing partner that provides a full suite of services from concept to production, today announced the appointment of Rachele Lehr as the Chief Human Resources Officer, effective March 13, 2023.
  • Lehr brings to MEC a decade of human resource leadership experience within the machinery and manufacturing industry.
  • “We are pleased to welcome Rachele to MEC’s executive leadership team,” said Jag Reddy, President and CEO of Mayville Engineering Company.
  • “Rachele is an experienced executive with a track record of building and leading impactful teams in both Human Resources and other functions.

CCMR3 Onboards 24-year Industry Veteran To Vice President of Execution

Retrieved on: 
Thursday, March 9, 2023
ACA International, MSP, Growth, PPMS, Blueprint, HCI, Lehr, Management, L.L.C, Capital punishment

SYRACUSE, N.Y., March 9, 2023 /PRNewswire/ -- CCMR3, a leading provider of accounts receivable and collection services, today announced the promotion of Christian Lehr to Vice President of Execution.

Key Points: 
  • SYRACUSE, N.Y., March 9, 2023 /PRNewswire/ -- CCMR3, a leading provider of accounts receivable and collection services, today announced the promotion of Christian Lehr to Vice President of Execution.
  • Since 1999, Christian Lehr has served as the Vice President and Chief Operating Officer of Healthcare-I, L.L.C., a healthcare receivables management company out of Phoenix, Arizona.
  • "CCMR3 is poised to grow significantly in 2023 and be a leader in the accounts receivable industry," says Lehr.
  • "As the Vice President of Execution, I can provide the CEO and management team with the insights I've gained over the last two decades in the industry.

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Lehr, Breast cancer, Endometrial cancer, PR, Menarini, Breast, CD3, Marketing, ER, Safety, Fulvestrant, Toxicity, Female, Context, SMILE, CLDN6, Cancer, Therapy, Chromatin, Patient, PFS, Pharmaceutical industry

PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer.

Key Points: 
  • Preliminary Phase 2 findings highlight a 4-month progression free survival (PFS) rate of 44%, and favorable safety and tolerability.
  • The data were presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).
  • Data from the Phase 1b portion of the trial is expected in Q4 2023.
  • ONA-XR is currently being evaluated in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in PR+ breast, ovarian and endometrial cancers.

Monvera Glass Decoration Celebrates its 15th Anniversary with Continued Investment in Growth and Expansion

Retrieved on: 
Thursday, December 1, 2022
Cosmetics, Beer, Interstate 580, Interstate Highway System, Glass, Printing, Ford Motor Company Assembly Plant, UV, Lehr, Interstate 80, CBD, Wine, Boisset Collection, Warehouse

RICHMOND, Calif., Dec. 1, 2022 /PRNewswire-PRWeb/ -- Monvera Glass Decoration, an industry leader in screen printed bottles is celebrating its 15th anniversary with a further expansion of its printing and warehouse facility and a newly published website.

Key Points: 
  • RICHMOND, Calif., Dec. 1, 2022 /PRNewswire-PRWeb/ -- Monvera Glass Decoration, an industry leader in screen printed bottles is celebrating its 15th anniversary with a further expansion of its printing and warehouse facility and a newly published website.
  • Monvera's production and warehouse facility has grown to 82,000 square feet within the historic Ford Assembly Building on the waterfront in Richmond, California.
  • The addition of this new warehouse space marks our 4th major expansion", says Caitriona Anderson, Monvera's VP of Sales & Marketing.
  • Monvera is an industry leader in glass bottle decoration specializing in screen-printed labels.

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Ovary, Private Securities Litigation Reform Act, PFS, Lehr, IND, Anastrozole, Forward-looking statement, Clinical trial, Endometrial cancer, Nasdaq, CLDN6, Intention, New Drug Application, G&A, SMILE, Fulvestrant, Therapy, R, Cancer, Jefferson Health, CD3, U.S. Securities and Exchange Commission, Breast, Company, GCT, Memorial Sloan Kettering Cancer Center, Program, Female, Research, SERD, Breast cancer, Patient, Granulosa cell tumour, Woman, CEO, Context, Insurance, Pharmaceutical industry, Health insurance, Dietary supplement

PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • These achievements underscore our commitment to creating new standards of care in the womens oncology field, said Martin Lehr, CEO of Context Therapeutics.
  • Our expected cash runway into Q1 2024 gives us the financial flexibility to execute on the advancement of our pipeline targeting female cancers.
  • Net Loss: Context reported a net loss of $3.9 million for third quarter 2022, as compared to $1.4 million for the same period in 2021.
  • Context Therapeutics Inc. (Nasdaq: CNTX)is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers.

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
Traction, Science, B cell, Magneto, Patient, Injury, Back pain, Oracle Fusion Applications, Research, SIX Swiss Exchange, Kuros, Veni, vidi, vici, TGA, Company, Spine, Safety, Sustainable Development Technology Canada, FDA, Lehr, Surgeon, Human, Medical imaging, Pharmaceutical industry

*2-4

Key Points: 
  • *2-4
    MagnetOs Flex Matrix is intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine.
  • In the posterolateral spine, MagnetOs Flex Matrix must be hydrated with bone marrow aspirate and used as an extender to autograft bone.
  • Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain.
  • MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
Traction, Month, Science, B cell, Magneto, Family, Patient, Injury, Back pain, Oracle Fusion Applications, Research, Surgeon, SIX Swiss Exchange, NASS, Kuros, CT, Solution, TGA, Company, Spine, Safety, Sustainable Development Technology Canada, FDA, Lehr, North American Spine Society, Veni, vidi, vici, Human, Medical imaging, Computer data storage, Pharmaceutical industry

Schlieren (Zurich), Switzerland, 11 October, 2022 Kuros Biosciences (Kuros or the Company), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on MagnetOs bone graft at the 38th Annual Meeting of the North American Spine Society (NASS), being held in Chicago October 12 to 15, 2022, in addition to completing a full commercial launch of MagnetOs Flex Matrix.

Key Points: 
  • Schlieren (Zurich), Switzerland, 11 October, 2022 Kuros Biosciences (Kuros or the Company), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on MagnetOs bone graft at the 38th Annual Meeting of the North American Spine Society (NASS), being held in Chicago October 12 to 15, 2022, in addition to completing a full commercial launch of MagnetOs Flex Matrix.
  • This first data, from the Companys five planned randomized controlled trials for MagnetOs, compares MagnetOs Granules to the gold standard of autograft bone.
  • The interim data exceed expectations for performance and validate MagnetOs as an augmented bone grafting option.
  • Details of the NASS presentations:
    t: +41 44 733 47 47t: +41 78 680 0538
    MagnetOs isn't like other bone grafts.

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Retrieved on: 
Tuesday, September 27, 2022
PR, Bispecific monoclonal antibody, Breast, Path integral molecular dynamics, Granulosa cell tumour, Woman, Twitter, Lehr, Food, IND, Intention, LinkedIn, Company, MBCA, Private Securities Litigation Reform Act, Context, Therapy, Forward-looking statement, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Breast cancer, CEO, Endometrial cancer, Female, CLDN6, Nasdaq, Climate, SERD, New Drug Application, Biotechnology, GLOBE, CD3, Pharmaceutical industry

PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.

Key Points: 
  • PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.
  • Context has been fortunate to collaborate with two tremendous organizations The Menarini Group and Integral Molecular.
  • Context Therapeutics Inc. (Nasdaq: CNTX)is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers.
  • Context is also developing a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development.